In a rapid-autopsy cohort, Eric G. Bluemn and colleagues classified metastatic lesions using AR and neuroendocrine markers and observed that, with widespread use of potent AR pathway inhibitors (e.g., enzalutamide and abiraterone), the proportion of double-negative metastatic prostate cancer (DNPC; AR−/NE−) increased. This evidence concerns the gene AR and metastatic prostate carcinoma.